Codexis Inc.

Company Overview

Founded in 2002, Codexis Inc. is a protein-engineering company involved in multiple industries, including pharmaceuticals, fine chemicals, biotherapeutics, food and beverage, and agriculture. The company develops proprietary biocatalysts (i.e., enzymes) or microbes that initiate or accelerate chemical reactions.

Codexis is focused on a synthetic biology platform that can develop enzymes for specialized purposes. Code Evolver, the company’s platform, creates libraries of gene variants encoding biocatalysts with novel functions. This gene-variant library is then recombined or shuffled, creating new variants. The resulting DNA sequences are screened for novel catalytic functions as part of directed-evolution programs. High-throughput screening methods are used to select those sequences with desired phenotypes. Code Evolver allows client customers to evolve and optimize biocatalysts to perform specific and wanted chemical reactions at the commercial level. Codexis is also using its technology to develop an early-stage enzyme therapeutic product candidate for treating patients with phenylketonuria (PKU) through oral administration. It is partnered with Nestle HealthScience in this program.

Financial Highlights (FY 2023)

Company's Business Segments

• Product : This segment consists of sales of biocatalysts, pharmaceutical intermediates, and Codex biocatalyst panels and kits.
• Research and Development : This segment includes license, technology access, exclusivity fees, research services fees, milestone payments, royalties, optimization, and screening fees